Vetoquinol (VETO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vetoquinol (VETO) has a cash flow conversion efficiency ratio of 0.026x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€14.72 Million ≈ $17.21 Million USD) by net assets (€567.53 Million ≈ $663.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Vetoquinol free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
Vetoquinol - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Vetoquinol's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of Vetoquinol for the company's overall valuation and market capitalisation.
Vetoquinol Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vetoquinol ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Foxsemicon Integrated Technology Inc
TW:3413
|
0.038x |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
0.037x |
|
Nanjing Xinlian Electronics Co Ltd
SHE:002546
|
0.029x |
|
Miracle Automation Engineering
SHE:002009
|
0.008x |
|
Retail Estates - Sicafi
BR:RET
|
0.026x |
|
Hunan Er Kang Pharmaceutical
SHE:300267
|
0.040x |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
-0.116x |
|
Top Energy Shanxi Co Ltd
SHG:600780
|
0.054x |
Annual Cash Flow Conversion Efficiency for Vetoquinol (2004–2024)
The table below shows the annual cash flow conversion efficiency of Vetoquinol from 2004 to 2024. View Vetoquinol stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €575.93 Million ≈ $673.33 Million |
€85.83 Million ≈ $100.34 Million |
0.149x | -12.13% |
| 2023-12-31 | €527.11 Million ≈ $616.25 Million |
€89.39 Million ≈ $104.51 Million |
0.170x | +30.77% |
| 2022-12-31 | €484.66 Million ≈ $566.62 Million |
€62.85 Million ≈ $73.48 Million |
0.130x | -36.20% |
| 2021-12-31 | €441.35 Million ≈ $515.99 Million |
€89.72 Million ≈ $104.89 Million |
0.203x | -18.05% |
| 2020-12-31 | €371.83 Million ≈ $434.71 Million |
€92.23 Million ≈ $107.83 Million |
0.248x | +84.03% |
| 2019-12-31 | €385.98 Million ≈ $451.25 Million |
€52.02 Million ≈ $60.82 Million |
0.135x | +29.18% |
| 2018-12-31 | €363.08 Million ≈ $424.48 Million |
€37.88 Million ≈ $44.29 Million |
0.104x | -15.03% |
| 2017-12-31 | €335.73 Million ≈ $392.50 Million |
€41.23 Million ≈ $48.20 Million |
0.123x | -10.05% |
| 2016-12-31 | €316.48 Million ≈ $369.99 Million |
€43.20 Million ≈ $50.51 Million |
0.137x | +1.61% |
| 2015-12-31 | €289.49 Million ≈ $338.45 Million |
€38.90 Million ≈ $45.47 Million |
0.134x | -12.68% |
| 2014-12-31 | €268.40 Million ≈ $313.78 Million |
€41.30 Million ≈ $48.28 Million |
0.154x | +29.18% |
| 2013-12-31 | €235.96 Million ≈ $275.86 Million |
€28.11 Million ≈ $32.86 Million |
0.119x | -20.61% |
| 2012-12-31 | €228.01 Million ≈ $266.57 Million |
€34.21 Million ≈ $39.99 Million |
0.150x | +5.70% |
| 2011-12-31 | €211.29 Million ≈ $247.02 Million |
€29.99 Million ≈ $35.06 Million |
0.142x | -23.87% |
| 2010-12-31 | €184.27 Million ≈ $215.43 Million |
€34.36 Million ≈ $40.17 Million |
0.186x | -27.85% |
| 2009-12-31 | €154.95 Million ≈ $181.15 Million |
€40.05 Million ≈ $46.82 Million |
0.258x | +61.72% |
| 2008-12-31 | €137.05 Million ≈ $160.23 Million |
€21.90 Million ≈ $25.61 Million |
0.160x | -45.09% |
| 2007-12-31 | €127.87 Million ≈ $149.49 Million |
€37.22 Million ≈ $43.51 Million |
0.291x | +38.50% |
| 2006-12-31 | €111.15 Million ≈ $129.94 Million |
€23.36 Million ≈ $27.31 Million |
0.210x | -39.22% |
| 2005-12-31 | €86.82 Million ≈ $101.50 Million |
€30.01 Million ≈ $35.09 Million |
0.346x | +19.09% |
| 2004-12-31 | €71.38 Million ≈ $83.45 Million |
€20.72 Million ≈ $24.23 Million |
0.290x | -- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more